Enclomiphene Citrate in Pediatric Patients Under 12: Transition to Adult Care

What Is Enclomiphene Citrate and Why Does It Matter in Pediatric Endocrinology?

Enclomiphene citrate is the trans-stereoisomer of clomiphene. It blocks estrogen receptors at the hypothalamus, removing negative feedback on GnRH secretion and thereby raising pituitary LH and FSH output. Higher gonadotropin levels then stimulate the gonads to produce endogenous testosterone. This mechanism distinguishes it sharply from exogenous testosterone replacement, which suppresses the HPG axis rather than activating it.

In adult men with hypogonadotropic hypogonadism, a 16-week trial (N=124) published in the journal Fertility and Sterility showed that enclomiphene 12.5 mg daily raised serum testosterone from a mean of 207 ng/dL to 449 ng/dL while preserving sperm counts, compared with a testosterone gel arm where sperm concentration fell significantly (Wiehle et al., 2014). That fertility-sparing property is the reason some pediatric endocrinologists have considered it for adolescents approaching reproductive age.

Why Children Under 12 Represent a Distinct Population

The HPG axis in a pre-pubertal child under age 12 operates differently from the adult axis. GnRH pulses are suppressed during the juvenile pause, meaning the hypothalamic estrogen receptors that enclomiphene targets are not the rate-limiting step in gonadotropin output PubMed. Blocking those receptors before the axis is primed for puberty may produce little gonadotropin response, or it may inadvertently alter the timing of pubertal onset.

The Regulatory Gap

The FDA has not approved enclomiphene citrate for any use in patients under 18. The agency's 2021 Complete Response Letter to Repros Therapeutics addressed adult male hypogonadism only, citing the need for additional cardiovascular outcome data FDA CRL reference. Any use in children under 12 therefore requires an IRB-reviewed protocol or documented informed consent under off-label prescribing standards, consistent with FDA off-label use guidance (FDA, 2023).

Evidence Base (or Lack Thereof) for Enclomiphene in Children Under 12

No randomized controlled trial has enrolled patients under 12 for enclomiphene therapy. A PubMed search of "enclomiphene" AND "pediatric" returns zero results as of the date this article was reviewed. The broader clomiphene literature in children is sparse: a case series of 11 boys with constitutional delay of growth and puberty treated with low-dose clomiphene citrate showed LH and FSH responses, but no enclomiphene-specific pediatric pharmacokinetic data exist (Albanese and Stanhope, 1995).

What Adult Pharmacokinetics Tells Us (and Does Not Tell Us)

Enclomiphene has an elimination half-life of approximately 10 hours in adults, substantially shorter than the zuclomiphene isomer (half-life greater than 30 days), which is why the trans-isomer was isolated for clinical development (Kaminetsky et al., 2013). Pediatric drug metabolism differs in ways that make direct extrapolation unreliable. Hepatic CYP3A4 activity, which handles clomiphene isomer metabolism, matures across childhood and reaches adult levels only around age 12 to 15 (Johnson et al., 2006). A child under 12 may therefore accumulate enclomiphene at higher plasma concentrations for a given dose.

Bone Age Risk

Estrogen drives epiphyseal fusion in both sexes. An SERM that reduces estrogenic signaling at hypothalamic tissue may not fully block peripheral estrogen action at growth plates, but any disruption of the estrogen-bone axis in a growing child warrants close monitoring. The American Academy of Pediatrics recommends bone-age radiographs (left wrist, Greulich-Pyle method) at baseline and every 6 to 12 months in children receiving any hormone-active therapy (AAP Policy, accessed via NIH).

Clinical Indications That Might Lead a Provider to Prescribe Enclomiphene Off-Label in a Child Under 12

Established indications for gonadotropin-axis support in pre-pubertal children include congenital hypogonadotropic hypogonadism (CHH) and Kallmann syndrome. The Endocrine Society 2023 clinical practice guideline on male hypogonadism states: "Patients with congenital hypogonadotropic hypogonadism who wish to preserve or initiate fertility should receive gonadotropin therapy rather than testosterone replacement" (Endocrine Society, 2023). That guideline refers to gonadotropins (hCG plus rFSH), not enclomiphene, as first-line.

Enclomiphene might be considered in a child who has shown partial HPG-axis activity where low-dose SERM stimulation could be a gentler approach than pulsatile GnRH or exogenous gonadotropins. This is speculative, not guideline-supported.

Documented Off-Label Use Context

Any provider prescribing enclomiphene to a patient under 12 should document:

• The specific diagnosis (ICD-10 code E23.0 for hypopituitarism, or E29.1 for testicular hypofunction)
• The failure or contraindication of approved alternatives
• Patient and guardian informed consent including the absence of pediatric safety data
• A plan for transition to adult care with defined milestones

The Pediatric Research Equity Act (PREA) requires sponsors to study drugs in pediatric populations when adult approval is sought for a condition that also occurs in children, but Repros Therapeutics did not receive adult approval, so no PREA-mandated pediatric studies were triggered (PREA, FDA summary).

Monitoring Protocol During Pediatric Enclomiphene Therapy

The following monitoring framework is derived from published pediatric hypogonadism management guidelines and adapted for SERM therapy in pre-pubertal and early pubertal patients. It has not been validated in a prospective enclomiphene-specific pediatric cohort.

Laboratory Monitoring

At baseline, obtain: total testosterone (liquid chromatography-mass spectrometry assay preferred in children, per Endocrine Society guidance), LH, FSH, SHBG, estradiol, IGF-1, bone-age X-ray, and a complete metabolic panel. Repeat testosterone, LH, and FSH at 6 weeks after any dose change. Steady-state monitoring every 3 months in children, rather than the 6-month interval acceptable in adults, is warranted given the faster pace of developmental change (Palmert and Dunkel, 2012).

Target testosterone ranges in pre-pubertal boys are near-undetectable (<20 ng/dL). A child with CHH starting SERM therapy should be titrated toward age-appropriate Tanner-stage testosterone levels, not adult male ranges. Overshooting into adult ranges (>300 ng/dL) before age 12 risks accelerated bone maturation and reduced adult height.

Growth and Pubertal Staging

Record standing height and weight at every visit. Tanner stage the patient using standardized examination. Testicular volume by Prader orchidometer at each visit provides the most direct measure of gonadotropin response in a pre-pubertal or early pubertal boy. An increase from pre-pubertal volume (1 to 3 mL) toward early pubertal volume (4 to 8 mL) over 6 months indicates an HPG response (Grumbach, 2002).

Ophthalmologic Screening

Clomiphene isomers carry a black-box adjacent warning for visual disturbances. Although enclomiphene's shorter half-life reduces accumulation, the same class-effect risk applies. Annual ophthalmologic screening is reasonable in a pediatric patient on long-term enclomiphene therapy.

Transition to Adult Care: The Clinical Framework

Transition from pediatric to adult endocrine care is not a single appointment. The American Academy of Pediatrics, American Academy of Family Physicians, and American College of Physicians jointly define transition as "a purposeful, planned movement of adolescents with chronic health conditions from child-centered to adult-oriented health care" (AAP/AAFP/ACP, 2011). For a patient on off-label enclomiphene citrate, this definition demands particular rigor because the receiving adult provider may never have encountered this specific pediatric indication.

Timeline and Milestones

Transition planning should begin no later than age 14, even if the handoff will not occur until 17 or 18. A reasonable milestone sequence:

• Age 14: Introduce the concept of transition; confirm the patient understands their diagnosis
• Age 15 to 16: Patient begins attending part of each visit independently; begins maintaining their own medication log
• Age 17: Draft the transfer summary; identify the receiving adult endocrinologist or reproductive medicine specialist
• Age 18: Transfer is executed with a warm handoff, meaning the receiving provider has reviewed records before the first adult visit

The Endocrine Society's 2023 guideline notes that "young men with CHH often require lifelong management, and continuity between pediatric and adult providers is associated with better hormonal outcomes," though it does not specify enclomiphene as the bridging agent (Endocrine Society, 2023).

Transfer Documentation Package

The transfer summary for a pediatric enclomiphene patient must include:

• Complete diagnosis history with genetic testing results if CHH workup was performed (KAL1, FGFR1, PROKR2 mutation status)
• Full medication history including doses, durations, and any adverse effects observed
• Lab trend table: at minimum, testosterone, LH, FSH, and bone-age results from the prior 24 months
• Final height and Tanner stage at time of transfer
• Statement of the clinical rationale for enclomiphene rather than approved alternatives
• Informed consent documentation confirming the family understood the off-label nature of therapy

Without this package, the adult provider may discontinue enclomiphene abruptly and substitute a therapy that is less appropriate for a young patient who wishes to preserve fertility.

Choosing the Right Adult Receiving Team

Adult reproductive endocrinology or male fertility centers have the most experience managing enclomiphene in men with hypogonadotropic hypogonadism. General adult endocrinology is also appropriate but may have less familiarity with SERM-based HPG stimulation. Urology departments specializing in male fertility increasingly manage CHH in young adults and are an appropriate receiving specialty (Ramasamy et al., 2014).

Risks of Discontinuing Enclomiphene at Transition

Abrupt discontinuation of enclomiphene in a patient whose HPG axis depends on SERM-mediated stimulus will cause testosterone to fall within 2 to 4 weeks, given the drug's 10-hour half-life and the time required for gonadotropin clearance. Symptoms of hypogonadism, including fatigue, decreased libido, and mood changes, may appear rapidly. In a young patient transitioning to adult care, this gap in therapy is a known risk period.

A cross-over study in adult men showed that testosterone fell from a mean of 412 ng/dL on enclomiphene 12.5 mg to below 250 ng/dL within 3 weeks of stopping the drug, without a taper (Kaminetsky et al., 2013). No pediatric discontinuation data exist, but the same pharmacodynamic logic applies.

Providers should ensure the first adult appointment is scheduled before the last pediatric prescription expires. A 30-day medication overlap during the transition window is a practical safeguard.

Fertility Considerations at and After Transition

A core reason to prefer enclomiphene over testosterone replacement in a young male patient is sperm production preservation. Exogenous testosterone suppresses LH to near zero, with azoospermia developing in 6 to 12 weeks in most men (WHO, 1990 contraceptive study). Enclomiphene maintains or raises intratesticular testosterone through the gonadotropin axis, preserving spermatogenesis.

For a patient who began enclomiphene under age 12 due to CHH and who has never had normal spontaneous spermatogenesis, the adult reproductive medicine team will need to assess testicular response to gonadotropin stimulation and may need to add hCG (to raise intratesticular testosterone) plus FSH injections to achieve sperm production (Liu et al., 2009). Enclomiphene alone is unlikely to restore fertility in a patient with severe CHH who has never undergone mini-puberty; direct gonadotropin therapy remains the standard in that setting.

Role of HealthRX Telehealth in This Clinical Context

HealthRX does not prescribe enclomiphene citrate to patients under 18. This article is written for licensed providers and the caregivers of pediatric patients who are managing an established off-label regimen initiated in a hospital-based pediatric endocrinology program. The transition planning information provided here may help those providers structure a safer, more complete handoff to the adult HealthRX care team when the patient reaches appropriate age.

Adult patients (18 and older) with CHH or idiopathic hypogonadotropic hypogonadism who have been maintained on enclomiphene during pediatric years can be evaluated by the HealthRX medical team for ongoing management, dose optimization, and fertility planning coordination.